The Efficacy of Rupatadine fumarate on Pain

JRCT ID: jRCTs021190010

Registered date:18/10/2019

Basic Information

• Recruitment status: Suspended
• Health condition(s) or Problem(s) studied: herpes zoster
• Date of first enrollment: 10/02/2020
• Target sample size: 45
• Study type: Interventional
• Intervention(s): after diagnosis of herpes zoster, in addition to the conventional treatment, Rupatazine fumarate is given 10 mg / day per day for 13 weeks.

Outcome(s)

• Primary Outcome: Improvement rate of the visual analogue scale (VAS)
• Secondary Outcome: Improvement rate of The Dermatology Life Quality Index (DLQI)

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) age:20-years-old or older
2) patients with acute herpes zoster within 2 weeks

Exclude criteria

1) patients with severe liver, kidney, heart disease, or diabetes
2) patients receiving medications that affect pain
3) patients with hypersensitivity to rupatazine fumarate
4) pregnant and nursing patients

Related Information

• Primary Sponsor: kono michihiro